CapsoVision, Inc. (CV)
$
7.51
-0.02 (-0.27%)
Key metrics
Financial statements
Free cash flow per share
-0.1139
Market cap
374.3 Million
Price to sales ratio
27.6144
Debt to equity
0.0669
Current ratio
3.7653
Income quality
0.9075
Average inventory
3.1 Million
ROE
1.0509
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics
News
seekingalpha.com
CapsoVision, Inc. (CV) Q4 2025 Earnings Call Transcript
globenewswire.com
Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results
defenseworld.net
Shares of CapsoVision, Inc. (NASDAQ: CV - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $12.39, but opened at $10.85. CapsoVision shares last traded at $11.05, with a volume of 7,782 shares trading hands. Analysts Set New Price Targets Several equities research analysts have recently weighed in
zacks.com
CV seeks FDA clearance to add AI-based reading to CapsoCam Plus to boost diagnostic accuracy and streamline reviews.
feeds.benzinga.com
CapsoVision shares surged in after-hours trading following the appointment of David Garcia as senior vice president of finance.
globenewswire.com
SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares began trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.”
globenewswire.com
SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.” The offering is expected to close on July 3, 2025 subject to the satisfaction of customary closing conditions.
See all news
